Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, James Chih‐Hsin Yang et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Sanjay Popat et al.|The Lancet Oncology|2015Cited by 1.6k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLCMasahiro Tsuboi, Yi‐Long Wu, Roy S. Herbst et al.|New England Journal of Medicine|2023Cited by 605
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Ji‐Youn Han et al.|The Lancet Oncology|2020Cited by 413
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cellsWu‐Chou Su, Yeh|International Journal of Nanomedicine|2012Cited by 150